Mahbub Hasan

Researchers from King’s College London have called for urgent changes to the way new antibiotics are developed to address the growing problem of antimicrobial resistance (AMR). In a new review published in npj Antimicrobials and Resistance, the authors outline the scientific, economic, and regulatory barriers that are slowing progress in the fight against highly resistant

King’s and the UK Health Security Agency (UKHSA) have been awarded a joint grant to develop efflux-resistant antibiotics for treating lung infections in people with cystic fibrosis (CF). The grant of £100,000, given through the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate’s Collaborative Discovery Programme (CDP) and funded by the medical research charity LifeArc, supports

The investment raised at the close of its Series B funding round will enable Pheon Therapeutics (Pheon) to take three new Antibody-Drug Conjugates (ADCs), used to treat cancer, through clinical trials. Pheon Therapeutics, a biotech spinout with its origins in research carried out at the Institute of Pharmaceutical Sciences (IPS) at King’s, has raised $120

Pheon Therapeutics, which has its origins in research carried out in the Institute of Pharmaceutical Sciences (IPS), launched on Wednesday 28 September based on a $68 million Series A financing round. The spin-out is focused on the development of novel Antibody-Drug Conjugates (ADCs) for use in oncology, and now has a presence in both London